Not provided
Not provided
Not provided
Not provided
Not provided
6 patients were recuited. Due to inability of the tracer to detect regions of interest sufficiently, the trial was closed early.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to investigate the safety and potential effectiveness of the imaging compound 18F FPM for finding sites of malignancies.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| D-18F FPM | Experimental |
| |
| L-18F FPM | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 18F FPM | Radiation |
|
| Measure | Description | Time Frame |
|---|---|---|
| Safety of D-18F FPM and L-18F FPM administration as measured by occurrence of adverse clinical, biochemical or haematological events following 18F FPM administration | Up to 28 days following 18F FPM administration (+/- 7 days) |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of injected D-18F FPM and L-18F FPM dose in organs of interest. | 10, 30, 60 and 120 minutes post 18F FPM administration | |
| Percentage of unmetabolized D-18F FPM and L-18F FPM in plasma and urine after radiotracer administration. | 30 (plasma only) and 90 (plasma and urine) minutes post 18F FPM administration |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ben Solomon | Peter MacCallum Cancer Centre, Australia | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Peter MacCallum Cancer Centre | East Melbourne | Victoria | Australia |
Not provided
| ID | Term |
|---|---|
| D002294 | Carcinoma, Squamous Cell |
| ID | Term |
|---|---|
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Absorbed organ doses expressed as micro Sv/MBq of administered D-18F FPM and L-18F FPM, and whole body dose expressed as milliSv/200MBq of administered dose | 10, 30, 60 and 120 minutes post 18F FPM administration |
| D018307 |
| Neoplasms, Squamous Cell |